New Mexico Educational Retirement Board Has $516,000 Stock Holdings in Organon & Co. (NYSE:OGN)


New Mexico Educational Retirement Board trimmed its stake in Organon & Co. (NYSE:OGN – Get Rating) by 4.5% in the first quarter, HoldingsChannel reports. The firm owned 14,768 shares of the company’s stock after selling 700 shares during the period. New Mexico Educational Retirement Board’s holdings in Organon & Co. were worth $516,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of OGN. Man Group plc grew its holdings in Organon & Co. by 70.3% in the third quarter. Man Group plc now owns 25,243 shares of the company’s stock worth $828,000 after purchasing an additional 10,420 shares during the period. MML Investors Services LLC grew its holdings in shares of Organon & Co. by 63.2% during the third quarter. MML Investors Services LLC now owns 19,282 shares of the company’s stock valued at $632,000 after buying an additional 7,464 shares during the last quarter. LPL Financial LLC grew its holdings in shares of Organon & Co. by 9.4% during the third quarter. LPL Financial LLC now owns 111,108 shares of the company’s stock valued at $3,643,000 after buying an additional 9,554 shares during the last quarter. Squarepoint Ops LLC grew its holdings in shares of Organon & Co. by 231.1% during the third quarter. Squarepoint Ops LLC now owns 67,327 shares of the company’s stock valued at $2,208,000 after buying an additional 46,991 shares during the last quarter. Finally, National Asset Management Inc. grew its holdings in shares of Organon & Co. by 21.4% during the third quarter. National Asset Management Inc. now owns 16,358 shares of the company’s stock valued at $536,000 after buying an additional 2,882 shares during the last quarter. Institutional investors and hedge funds own 70.85% of the company’s stock.

OGN opened at $34.92 on Friday. The company’s 50-day moving average is $35.01 and its 200-day moving average is $33.98. Organon & Co. has a fifty-two week low of $28.42 and a fifty-two week high of $39.47. The firm has a market capitalization of $8.86 billion and a P/E ratio of 6.85.

Organon & Co. (NYSE:OGN – Get Rating) last released its quarterly earnings results on Thursday, May 5th. The company reported $1.65 earnings per share for the quarter, beating analysts’ consensus estimates of $1.31 by $0.34. Organon & Co. had a net margin of 20.42% and a negative return on equity of 103.33%. The company had revenue of $1.57 billion for the quarter, compared to analyst estimates of $1.52 billion. During the same period last year, the firm earned $1.56 earnings per share. The firm’s revenue was up 4.1% on a year-over-year basis. As a group, analysts predict that Organon & Co. will post 5.32 earnings per share for the current year.

The business also recently announced a quarterly dividend, which was paid on Thursday, June 16th. Shareholders of record on Monday, May 16th were paid a $0.28 dividend. This represents a $1.12 dividend on an annualized basis and a yield of 3.21%. The ex-dividend date of this dividend was Friday, May 13th. Organon & Co.’s payout ratio is 21.96%.

A number of research analysts have recently issued reports on the stock. Morgan Stanley reduced their price objective on shares of Organon & Co. from $37.00 to $35.00 and set an “equal weight” rating for the company in a report on Wednesday, April 6th. The Goldman Sachs Group assumed coverage on shares of Organon & Co. in a report on Wednesday, April 27th. They set a “buy” rating and a $40.00 target price for the company. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $39.20.

Organon & Co. Company Profile (GetRating)

Organon & Co, a health care company, develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally. Its women’s health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive.

Read More

Want to see what other hedge funds are holding OGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Organon & Co. (NYSE:OGN – Get Rating).

Institutional Ownership by Quarter for Organon & Co. (NYSE:OGN)



Receive News & Ratings for Organon & Co. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Organon & Co. and related companies with MarketBeat.com’s FREE daily email newsletter.

.

Leave a Reply

Your email address will not be published.

Back to top button